How did SIBN's Q4 earnings surprise impact its annual performance?

**SI-BONE's Q4 earnings surprise had a significant impact on its annual performance**, as evidenced by the following points:

1. **Record Revenue and Adjusted EBITDA Loss**: SI-BONE reported record worldwide revenue of $40.3 million for Q3 2024, reflecting a 19% growth. This marked a positive shift in revenue trajectory, although the company still reported a net loss of $6.6 million for the quarter. The adjusted EBITDA loss was only $200,000, a 94% improvement, indicating a path to profitability.
2. **Cumulative Net Income and Revenue**: Over the past four years, SI-BONE's net income remained negative, with the latest figure standing at -$30.91 million for 2024. However, total revenue showed a growing trend, reaching $167.18 million in 2024. The cumulative revenue for the four years was $106.41 million in 2022, $90.15 million in 2021, $138.89 million in 2023, and $167.18 million in 2024.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|SIBN|SIBN.O|SI-BONE|2021 Q1|4.14970247416223|-1.2242E7|185|
|SIBN|SIBN.O|SI-BONE|2021 Q2|-12.099101988454137|-1.3981E7|185|
|SIBN|SIBN.O|SI-BONE|2021 Q3|-67.53219337133207|-1.5872E7|185|
|SIBN|SIBN.O|SI-BONE|2021 Q4|-61.231763002561536|-1.4477E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q1|-42.21532429341611|-1.741E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q2|-32.41542092840283|-1.8513E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q3|10.798891129032258|-1.4158E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q4|22.808592940526353|-1.1175E7|185|
|SIBN|SIBN.O|SI-BONE|2023 Q1|36.099942561746126|-1.1125E7|185|
|SIBN|SIBN.O|SI-BONE|2023 Q2|39.469561929454976|-1.1206E7|185|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|SIBN|SIBN.O|SI-BONE|2021 Q1|21.52666309969681|2.0442E7|185|
|SIBN|SIBN.O|SI-BONE|2021 Q2|57.975656630365144|2.2194E7|185|
|SIBN|SIBN.O|SI-BONE|2021 Q3|9.389878761105384|2.2286E7|185|
|SIBN|SIBN.O|SI-BONE|2021 Q4|13.936054913294798|2.523E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q1|9.769102827511986|2.2439E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q2|15.2789042083446|2.5585E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q3|18.60360764605582|2.6432E7|185|
|SIBN|SIBN.O|SI-BONE|2022 Q4|26.646848989298455|3.1953E7|185|
|SIBN|SIBN.O|SI-BONE|2023 Q1|45.76407148268639|3.2708E7|185|
|SIBN|SIBN.O|SI-BONE|2023 Q2|30.17393003713113|3.3305E7|185|

3. **Earnings Expectations and Actuals**: Analysts expected SI-BONE to announce earnings of ($0.22) per share for Q4, which the company surpassed by $0.04. This positive surprise contributed to the annual performance, although the overall annual EPS was expected to be -$1.
4. **Operational Highlights and Future Outlook**: SI-BONE achieved significant progress towards profitability and received 510-K clearance for iFuse TORQ TNT. The company ended the quarter with over 1,200 active physicians, an increase of nearly 150. These factors, combined with the expectation of achieving positive Adjusted EBITDA in Q4 2024, suggest a promising future performance.

In conclusion, while SI-BONE's Q4 earnings surprise was a positive development, the cumulative effect over the past four years has resulted in negative net income. However, the trend towards profitability, coupled with record revenue and strategic advancements, provides a positive outlook for the company's future performance.